COVID-19
With the chaos in the workplace and in healthcare caused by the COVID-19 pandemic, experts predict that most major employers will not be looking to add any more disruption with significant changes to their benefit plans for 2021.
With many clinical trials on hold and COVID-19 studies the only new trials opening up, how are cancer researchers adapting to the new environment? Can lessons from COVID-19 facilitate improved clinical trial recruitment and retention in the future?
When oncology practices, ranging from small community clinics to larger hospital-based programs, were required to adapt their systems virtually overnight in response to the COVID-19 health crisis, almost no one anticipated that these would be long-term changes. However, as September approaches with no end in sight, it has become clear that oncologists will need to adapt revenue cycle management to long-term pandemic-related changes.
As many full-service hospitals and health systems remain overwhelmed due to the COVID-19 pandemic, community cancer providers have been able to offer certain services to patients that may not be available at other institutions. How have these providers adapted to meet patients’ changing needs, and how are they keeping their doors open under unprecedented pressure?
One of the most significant questions for payers in the COVID-19 health ecosystem is, “Will reimbursement parity for telehealth services continue?” Leading representatives of major managed care organizations debate the prospects.
From shuttered laboratory experiments and interrupted clinical trial enrollments to a “shadow curve” of delayed cancer diagnoses, comprehensive cancer centers and integrated delivery networks (IDNs) across the country continue to grapple with the fallout from COVID-19.
The COVID-19 pandemic has rapidly forced people from all over the world and all walks of life to change how they interact—no more hugs; no more handshakes; no more life as we knew it—at least for now.
Shortages, inventory management, and challenges of in-home care were just a few of the topics in AVBCC’s wide-ranging webinar on how COVID-19 is affecting oncology pharmacy.
As the COVID-19 pandemic stretches into its fifth month in the United States, advocacy groups providing support for patients with cancer are delivering essential support and services, while they worry about the long-term psychosocial impact on these patients and the future of clinical trials.
As we learn more about the complicated behavior of the COVID-19 virus, we have come to understand that overactivation of the patient’s own immune system can often be the most dangerous factor. In this webcast, top cancer experts discuss the latest studies investigating using anti-cancer therapies as treatments for COVID-19. What are some of the options and where does the research stand today?
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512